Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$1.80 -2.7%	$1.84	$1.60 ▼ $3.14	$693.73M	1.02	1.42 million shs	2.35 million shs
ESPR Esperion Therapeutics	$0.92 +4.4%	$1.40	$0.82 ▼ $3.94	$243.72M	0.86	5.66 million shs	4.84 million shs
LENZ LENZ Therapeutics	$26.87 -6.1%	$23.61	$14.42 ▼ $38.93	$788.01M	0.43	185,218 shs	191,481 shs
NUVB Nuvation Bio	$2.13	$1.95	$1.54 ▼ $3.97	$721.39M	1.47	2.11 million shs	2.07 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	0.00%	+1.69%	-1.64%	-5.26%	-27.42%
ESPR Esperion Therapeutics	0.00%	-3.16%	-42.86%	-56.19%	-56.81%
LENZ LENZ Therapeutics	0.00%	+12.80%	+1.28%	+9.45%	+69.42%
NUVB Nuvation Bio	0.00%	+8.40%	+13.60%	-15.31%	-19.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.5927 of 5 stars	2.0	4.0	0.0	2.8	0.0	1.3
ESPR Esperion Therapeutics	3.3755 of 5 stars	3.3	1.0	3.9	1.8	1.7	0.6
LENZ LENZ Therapeutics	1.8587 of 5 stars	3.6	0.0	0.0	3.2	2.5	0.0
NUVB Nuvation Bio	3.5931 of 5 stars	4.6	1.0	0.0	2.1	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	$3.50	94.44% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.42	597.46% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	73.43% Upside
NUVB Nuvation Bio	3.17	Buy	$7.83	267.76% Upside

Current Analyst Ratings Breakdown

Latest ESPR, NUVB, CRON, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$38.00 ➝ $51.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/27/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.62M	5.90	N/A	N/A	$2.87 per share	0.63
ESPR Esperion Therapeutics	$332.31M	0.55	N/A	N/A	($3.85) per share	-0.24
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$22.06 per share	N/A
NUVB Nuvation Bio	$7.87M	91.63	N/A	N/A	$2.76 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	-$73.96M	$0.10	N/A	60.00	1.74	-42.65%	-2.56%	-2.47%	5/8/2025 (Estimated)
ESPR Esperion Therapeutics	-$209.25M	-$0.25	N/A	N/A	N/A	-29.37%	N/A	-10.77%	5/6/2025 (Estimated)
LENZ LENZ Therapeutics	-$124.65M	-$4.77	N/A	N/A	N/A	N/A	-58.48%	-55.50%	5/14/2025 (Estimated)
NUVB Nuvation Bio	-$75.80M	-$2.26	N/A	N/A	N/A	N/A	-21.89%	-17.86%	5/7/2025 (Estimated)

Latest ESPR, NUVB, CRON, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.56	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	N/A	N/A	N/A	$0.42 million	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	N/A	N/A	N/A	$54.97 million	N/A
3/19/2025	Q4 2024	LENZ LENZ Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.24	23.05
ESPR Esperion Therapeutics	N/A	1.85	1.37
LENZ LENZ Therapeutics	N/A	28.63	28.63
NUVB Nuvation Bio	N/A	9.57	9.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
ESPR Esperion Therapeutics	47.39%
LENZ LENZ Therapeutics	54.32%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
ESPR Esperion Therapeutics	1.00%
LENZ LENZ Therapeutics	38.40%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.41 million	356.14 million	Optionable
ESPR Esperion Therapeutics	200	198.15 million	195.07 million	Optionable
LENZ LENZ Therapeutics	110	27.54 million	16.94 million	N/A
NUVB Nuvation Bio	60	338.68 million	319.50 million	Optionable

ESPR, NUVB, CRON, and LENZ Headlines

Recent News About These Companies

Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Price Target at $7.83

April 26 at 1:11 AM | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Earns Market Outperform Rating from Analysts at JMP Securities

April 25 at 8:11 AM | marketbeat.com

Nuvation Bio initiated with an Outperform at Citizens JMP

April 24 at 11:18 PM | markets.businessinsider.com

JMP Securities Initiates Coverage of Nuvation Bio (NUVB) with Market Outperform Recommendation

April 23, 2025 | msn.com

Geode Capital Management LLC Raises Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB)

April 23, 2025 | marketbeat.com

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

April 22, 2025 | businesswire.com

Federated Hermes Inc. Sells 349,503 Shares of Nuvation Bio Inc. (NYSE:NUVB)

April 21, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Shares Down 6.4% - Should You Sell?

April 18, 2025 | marketbeat.com

Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 16, 2025 | insidermonkey.com

Nuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Fmr LLC

April 16, 2025 | marketbeat.com

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

April 14, 2025 | msn.com

Nuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Vanguard Group Inc.

April 14, 2025 | marketbeat.com

Insider Buying: Nuvation Bio Inc. (NYSE:NUVB) CEO Purchases 200,000 Shares of Stock

April 11, 2025 | marketbeat.com

David Hung Acquires 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) Stock

April 10, 2025 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) CEO David Hung Acquires 200,000 Shares

April 10, 2025 | insidertrades.com

Tuesday’s Insider Activity: Key Buys and Sells in US Stocks

April 9, 2025 | investing.com

Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple

April 9, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Reaches New 1-Year Low - What's Next?

April 9, 2025 | marketbeat.com

David Hung Buys 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) Stock

April 9, 2025 | insidertrades.com

Nuvation Bio (NYSE:NUVB) Stock Price Up 5.4% - Here's What Happened

April 4, 2025 | marketbeat.com

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

April 2, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
By Jeffrey Neal Johnson | April 6, 2025
View Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves
By Thomas Hughes | April 11, 2025
View Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves

ESPR, NUVB, CRON, and LENZ Company Descriptions

Cronos Group NASDAQ:CRON

$1.80 -0.05 (-2.70%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.81 +0.01 (+0.56%)

As of 04/25/2025 07:42 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Esperion Therapeutics NASDAQ:ESPR

$0.92 +0.04 (+4.39%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.93 +0.01 (+1.09%)

As of 04/25/2025 07:58 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

LENZ Therapeutics NASDAQ:LENZ

$26.87 -1.74 (-6.08%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$26.92 +0.05 (+0.20%)

As of 04/25/2025 04:48 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Nuvation Bio NYSE:NUVB

$2.13 0.00 (0.00%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$2.09 -0.04 (-1.88%)

As of 04/25/2025 07:46 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time